APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

Annals of Neurology

Volumn 67, Issue 1, 2010, Pages 122-131

  Morris, John C ^a   Roe, Catherine M ^a   Xiong, Chengjie ^a   Fagan, Anne M ^a   Goate, Alison M ^a   Holtzman, David M ^a   Mintun, Mark A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; TAU PROTEIN;

ADULT; AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENOTYPE; HUMAN; MALE; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SENILE PLAQUES; TAU PROTEINS; THIAZOLES;

EID: 77649314191     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21843     Document Type: Article

References (77)

1. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J Mol Neurosci 2001;17:101-118.
2. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138-144.
3. Troncoso JC, Cataldo M, Nixon RA, et al. Neuropathology of preclinical and clinical late-onset Alzheimer's disease. Ann Neurol 1998;43:673-676.
4. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1168-1174.
5. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
6. Schmitt FA, Davis DG, Wekstein DR, et al. Preclinical AD revisited. Neuropathology of cognitively normal older adults. Neurology 2000;55:370-376.
7. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-1095.
8. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837-1844.
9. Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-1036.
10. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-282.
11. Cork LC. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genet 1990;37:282-286.
12. Stern Y. Cognitive reserve and Alzheimer disease. Alz Dis Assoc Disord 2006;20:112-117.
13. Mortimer JA, Borenstein AR, Gosche KM, et al. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol 2008;18:218-223.
14. Roe CM, Mintun MA, D'Angelo G, et al. Alzheimer disease and cognitive reserve: variation of education with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 2008;65:1467-1471.
15. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology 2007;68:1718-1725.
16. Ewers M, Zhong Z, Burger K, et al. Increased CSF-BACE I activity is associated with ApoE-E4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008;131:1252-1258.
17. Jack CR, Lowe VJ, Senjem ML, et al. 11C PIB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
19. Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009;72:1048-1055.
20. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65:176-183.
21. Sunderland T, Linker G, Mirza N, et al. Decreased β-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-2103.
22. Clark CM, Xie S, Chittams J, et al. CSF tau and beta-amyloid: how well do these biomarkers reflect autopsy confirmed dementia diagnoses? Arch Neurol 2003;60:1696-1702.
23. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
24. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-1645.
25. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008;65:1304-1309.
26. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann Neurol 2006;59:512-519.
27. Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343-349.
28. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
29. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
30. Simonsen AH, McGuire J, Hansson O, et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 2007;64:366-370.
31. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465.
32. Gustafson DR, Skoog I, Rosengren L, et al. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78:461-464.
33. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007;69:631-639.
34. Blennow K, deLeon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
35. Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
36. Farrer L, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
37. Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008;83:623-632.
38. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-affinity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-1981.
39. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-184.
40. Talbot C, Lendon C, Craddock N, et al. Protection against Alzheimer's disease with apoE e2 [letter]. Lancet 1994;343:1432-1433.
41. Jiang Q, Lee DYD, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Aβ. Neuron 2008;58:681-693.
42. Ma J, Yee A, Brewer HB Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994;372:92-94.
43. DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that apoE regulates extracellular Aβ metabolism in vivo. Neuron 2004;41:193-202.
44. Holtzman D, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000;97:2892-2897.
45. Fagan AM, Watson M, Parsadanian M, et al. Human and murine apoE markedly influence Abeta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 2002;9:305-318.
46. Polvikoski T, Sulkava R, Haltia M. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med 1995;333:1242-1247.
47. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:9649-9653.
48. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
49. Bennett DA, Wilson RS, Schneider JA, et al. Apolipoprotein E E4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 2003;60:246-252.
50. Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009;72:1487-1494.
51. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:6820-6825.
52. Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry 2009;66:81-87.
53. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326 -335.
54. Coats MA, Morris JC. Antecedent biomarkers of Alzheimer's disease: the Adult Children Study. J Geriatr Psychiatry Neurol 2005;18:242-244.
55. Storandt M, Grant EA, Miller JP, et al. Longitudinal course and neuropathological outcomes in original versus revised MCI and in PreMCI. Neurology 2006;67:467-473.
56. Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 1975;12:189-198.
57. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
58. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alz Dis Assoc Disord 2006;20:210-216.
59. Storandt M, Grant EA, Miller JP, et al. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 2002;59:1034-1041.
60. Cirrito JR, May PC, O'Dell MA, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003;23:8844-8853.
61. Mintun MA, LaRossa GN, Sheline YI, et al. [11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
62. Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754.
63. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3-D Proportional System: An Approach to Cerebral Imaging. Stuttgart, Germany: Thieme Medical Publishers; 1988.
64. Buckner RL, Head D, Parker J, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004;23:724-738.
65. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
66. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models. Cary, NC: SAS Institute; 1996.
67. Kauwe JSK, Wang J, Mayo K, et al. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 2009;10:13-17.
68. Tapiola T, Alafuzoff I, Herruka SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-389.
69. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population. Arch Neurol 2003;60:1119-1122.
70. Yaffe K, Cauley J, Sands L, et al. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol 1997;54:1110-1114.
71. Bretsky P, Guralnik JM, Launer L, et al. The role of APOE-e4 in longitudinal cognitive decline; MacArthur studies of successful aging. Neurol 2003;60:1077-1081.
72. Haan MN, Shemanki L, Jagust WJ, et al. The role of APOE e4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282:40-46.
73. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
74. Wishart HA, Saykin AJ, McAllister TW, et al. Regional brain atrophy in cognitively intact adults with a single APOEE4 allele. Neurology 2006;67:1221-1224.
75. Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009;132:1067-1077.
76. Chen K, Reiman EM, Alexander GE, et al. Correlations between apolipoprotein E E4 gene dose and whole brain atrophy rates. Am J Psychiatry 2007;164:916-921.
77. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;837-842.